Boston Scientific
Trade Boston Scientific 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BSX
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments.
BSX Key Statistics
Stock Snapshot
As of today, Boston Scientific(BSX) shares are valued at $101.58. The company's market cap stands at 150.56B, with a P/E ratio of 54.00.
During the trading session on 2025-11-29, Boston Scientific(BSX) shares reached a daily high of $101.73 and a low of $100.50. At a current price of $101.58, the stock is +1.1% higher than the low and still -0.2% under the high.
Trading volume for Boston Scientific(BSX) stock has reached 2.82M, versus its average volume of 9.87M.
Over the past 52 weeks, Boston Scientific(BSX) stock has traded between a high of $109.50 and a low of $85.98.
Over the past 52 weeks, Boston Scientific(BSX) stock has traded between a high of $109.50 and a low of $85.98.
BSX News
Below is Validea's guru fundamental report for BOSTON SCIENTIFIC CORP (BSX). Of the 22 guru strategies we follow, BSX rates highest using our P/E/Growth Investo...
Earlier this week, Boston Scientific reported quarterly revenues of US$5.07 billion, reflecting over 20% year-on-year growth and surpassing analysts' expectatio...
Bearish flow noted in Boston Scientific (BSX) with 1,475 puts trading, or 1.3x expected. Most active are Dec-25 96 puts and Dec-25 100 calls, with total volume...
Analyst ratings
97%
of 36 ratingsMore BSX News
Boston Scientific BSX posted an adjusted gross margin of 71% in the third quarter of 2025, representing a 60-basis-point (bps) improvement compared to the prior...
Boston Scientific (BSX) has seen its stock price fluctuate over the past month, edging down by 3% despite positive annual revenue and net income growth. Investo...